Viewing Study NCT03866369


Ignite Creation Date: 2025-12-24 @ 11:09 PM
Ignite Modification Date: 2026-02-22 @ 5:24 PM
Study NCT ID: NCT03866369
Status: COMPLETED
Last Update Posted: 2019-11-01
First Post: 2019-03-01
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Multiple Ascending Dose Phase I Study in Order to Define Lanifibranor (IVA337) Supra-thjerapeutic Dose
Sponsor: Inventiva Pharma
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Healthy Subjects View
Keywords:

Keywords

Keyword Brief Keyword Text View
None healthy male volunteers View
None multiple ascending dose View
None supra-therapeutic dose View